460 Studies Now Enrolling
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
| Sponsor: | ECOG-ACRIN Cancer Research Group |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAR9102 |
| U.S. Govt. ID: | NCT03115333 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this research study is to test whether the advanced perfusion MRI done prior to starting Bevacizumab and a few weeks after starting Bevacizumab can determine your response to the treatment better than the standard MRI performed at typical time points. The researchers want to see if this type of advanced MRI is better or the same as what is usually used for monitoring your brain cancer.
This study is closed
Do You Qualify?
| Are you 18 years of age or older? | Yes | No |
| Do you have a confirmed intracranial glioblastoma or gliosarcoma? | Yes | No |
| Have you not previously received a bevacizumab-containing regimen (i.e., this must be the first bevacizumab-containing therapy | Yes | No |
| Can you tolerate brain MRI scans with dynamic intravenous gadolinium-based contrast agent injections? | Yes | No |